Clinical Trial Update: ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of ONO-4538 (nivolumab) in patients with advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ONO-4538

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Advanced Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED